SUTRO BIOPHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.215 USD | -2.66% |
|
+1.81% | -1.75% |
| May. 13 | Sutro Biopharma Q1 Loss Widens, Revenue Rises | MT |
| May. 13 | Earnings Flash (STRO) SUTRO BIOPHARMA Posts Q1 Revenue $13M | MT |
Financials (USD)
| Sales 2024 * | 59.32M | Sales 2025 * | 62.54M | Capitalization | 346M |
|---|---|---|---|---|---|
| Net income 2024 * | -243M | Net income 2025 * | -268M | EV / Sales 2024 * | 1.99 x |
| Net cash position 2024 * | 228M | Net cash position 2025 * | 376M | EV / Sales 2025 * | -0.49 x |
| P/E ratio 2024 * |
-1.19
x | P/E ratio 2025 * |
-1.32
x | Employees | 300 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.99% |
More Fundamentals
* Assessed data
More news
Latest transcript on Sutro Biopharma, Inc.
More recommendations
More press releases
More news
| 1 day | -2.66% | ||
| 1 week | +1.81% | ||
| Current month | -0.24% | ||
| 1 month | +24.15% | ||
| 3 months | -14.15% | ||
| 6 months | +61.49% | ||
| Current year | -1.75% |
1 week
4.01
4.47
1 month
3.705.09
Current year
3.206.13
1 year
2.016.13
3 years
2.0123.70
5 years
2.0128.30
10 years
2.0128.30
| Managers | Title | Age | Since |
|---|---|---|---|
William Newell
CEO | Chief Executive Officer | 66 | 09-01-13 |
Jane Chung
PSD | President | 53 | 21-08-08 |
Edward Albini
DFI | Director of Finance/CFO | 66 | 13-01-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Connie Matsui
CHM | Chairman | 70 | 19-06-23 |
James Panek
BRD | Director/Board Member | 71 | 20-01-06 |
Daniel Petree
BRD | Director/Board Member | 68 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 0 M€ | 0.00% | - | |
| 0.02% | 0 M€ | 0.00% | - | |
| 0.01% | 1,487 M€ | +7.77% | - | |
| 0.01% | 9 M€ | +9.86% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 4.225 | -2.42% | 444,305 |
| 24-05-30 | 4.33 | +1.88% | 466,561 |
| 24-05-29 | 4.25 | +1.67% | 608,917 |
| 24-05-28 | 4.18 | +0.97% | 698,397 |
| 24-05-24 | 4.14 | +1.47% | 528,017 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotes
Sutro Biopharma, Inc. is a clinical-stage oncology company. The Company is engaged in developing site-specific and novel-format antibody drug conjugates (ADCs) enabled by its integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. The Companyâs advanced product candidate is STRO-002 (luveltamab tazevibulin, or luvelta), an ADC directed against folate receptor-alpha (FolRa), for patients with FolRa-expressing cancers, including ovarian cancer. In addition, it uses luvelta to treat pediatric patients with relapsed/refractory CBFA2T3-GLIS2 and acute myeloid leukemia. It also has two preclinical product candidates, STRO-003 and STRO-004. These product candidates are single homogeneous ADCs directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1), and tissue factor (TF), each of which is being developed for the treatment of solid tumors.
Calendar
2024-06-06
- Jefferies Global Healthcare Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
4.225
USD
Average target price
12.6
USD
Spread / Average Target
+198.22%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -1.75% | 345M | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- STRO Stock
